Month: August 2021

Figure 1Plan view of the PGP site showing the location of the drill pads in relation to the mill building and existing resources. Results from drill pad NL-W01 were previously reported.VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce additional high-grade results in step-out and exploration drillholes from the ongoing 25,000m drill program at the Company’s Premier Gold Project (“PGP”). Before moving to higher elevations, drilling this season to date has focused on the area to the northwest of the Premier/Northern Light zones. High-grade gold was intercepted from multiple drill locations and at various depths, expanding previously identified areas of mineralization and adding new zones. Highlights from the...

Executive team to update investors via webinar on recent business developments and the acquisition of Xcite Interactive LOS ANGELES, Aug. 09, 2021 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) announced today that it will host an investor webinar on Monday, August 16, 2021, to provide an update on the business. The webinar will begin at 2:00 p.m. PT (5:00 p.m. ET). Investors will be able to access the event in the investor relations section of the company’s website at https://ir.versussystems.com/. Versus Systems’ executive management team will discuss second quarter 2021 developments, details regarding the integration of Xcite Interactive, and the company’s strategies for growth and related milestones. Investors may register for the webinar here. Questions for the Q&A session may be sent...

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet (neovascular) age-related macular degeneration (AMD). Following formal authorization from the regulatory agency Health Canada, patient enrollment in the two concurrent Phase 3 registrational clinical trials, ShORe (Study of OPT-302 in combination with Ranibizumab) and COAST (Combination OPT-302 with Aflibercept Study) can now begin in Canada. The goal of the two studies is to evaluate the benefits of the Company’s VEGF-C/D ‘trap’ inhibitor, OPT-302, for wet AMD in treatment-naïve...

CHICAGO and WARMINSTER, Penn., Aug. 09, 2021 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (GTI) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ Dispensaries, today announced it will open Rise Warminster, the 16th Rise™ location in Pennsylvania and 62nd store nationwide, on Tuesday, August 10. Profits from the first day of sales will be donated to National Giving Alliance (NGA) which works to improve the quality of life for homeless, low-income and moderate-income children, women and men by collecting and distributing new clothes, linens and toiletries. “The opening of Rise Warminster marks number 16 in the Commonwealth, our deepest dispensary footprint serving a single market and a true testament to the support of cannabis for well-being in communities across Pennsylvania,”...

ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1 mL Vial Now Commercially Available to U.S. Healthcare Providers RAMSEY, N.J. and BOCA RATON, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients. “The availability of these additional NABI-HB and BIVIGAM vial sizes meaningfully enhances ADMA’s go-to-market offering for its commercial Immune Globulin (“IG”) product portfolio and allows for more versatile utilization...

Cerence Third Quarter HighlightsRevenue grew 29% year-over-year Exceeded company quarterly guidance on key GAAP and non-GAAP profitability metrics Increased FY24 revenue Target from $600M to $700M, and improved key profitability metrics Record number of auto SOPs (Start Of Production) from over 15 auto OEMs Strategic collaborations announced in the quarter with Sirius XM, Visteon and HarmanBURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today reported its third fiscal quarter 2021 results for the quarter ended June 30, 2021. Results Summary (1)(in millions, except per share data)    Three Months Ended     Nine Months Ended      June 30,     June 30,      2021       2020       2021       2020    GAAP Revenue     $96.8         $75.2         $289.1         $239.7    GAAP...

Else readying for distribution at online platforms of Nation’s Leading Grocery Retail Chain VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company, announces that it will be expanding into owned online marketplaces by Q4, 2021 with its Plant-Based Complete Nutrition products for Toddlers. The expansion also will place else at Kroger-owned Vitacost.com, an E-commerce leader in the healthy/organic foods space. “Being a part of Kroger’s E-commerce platforms mark a major step forward for our online growth strategy,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “Kroger’s large on-line presence as a grocery leader, will significantly increase the accessibility...

CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine. TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors. CD47 binds to SIRPα on macrophages and delivers a “don’t eat me” signal that inhibits the ability of macrophages to engulf and destroy cancer cells. Preclinical studies have shown that TTI-622 exhibits anti-tumor activity against AML cells as a monotherapy that is...

On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021 Positive feedback from FDA clarifies potential path forward in ASD Cash runway well into the first half of 2024; $85.8 million at June 30, 2021DEVON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2021, and provided an overview of recent operational highlights and a pipeline update. “We continue to make progress across our portfolio, particularly in FXS in which our confirmatory pivotal Phase 3 trial, RECONNECT, is expected to start in the third quarter of 2021,” said...

Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET CHESTERBROOK, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the second quarter ended June 30, 2021, prior to the market open on Thursday, August 12th, 2021. Company management will host a conference call and webcast with the investment community at 8:00 a.m. (ET) that same day featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Bob Yoder, Chief Business Officer, Mark Demitrack, SVP and Chief Medical Officer and Barry Shin, SVP and Chief Financial Officer.Title: Trevena Second Quarter 2021...